← Back to all trials
Completed
NCT06905327
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
Conditions: Mild Hypertension
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 56
Sponsor: Novartis Pharmaceuticals
Location: Novartis Investigative Site Herston Queensland
Summary
This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
Eligibility Criteria
Inclusion Criteria:
* Healthy males or females aged 18 to 60 years, inclusive, at the time of informed consent. (Part A only).
* Males or females aged 18 to 72 years, inclusive, at the time of informed consent (Part B only).
* Body mass index (BMI) \>= 18 and \50 kg (Part A only).
* Body mass index (BMI) \>=18 and \50 kg (Part B only).
* Triplicate 12-lead electrocardiogram (ECG) after \>5 minutes resting without clinically significant findings at screening and Day -1.
* Mean sitting systolic blood pressure (SBP) of \>=130 and \
Source: ClinicalTrials.gov (NCT06905327). StuddyBuddy aggregates publicly available trial information.
